Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24340768 | 0.78 | MAPT (0.46) | LPAR1LPAR5MGLLMEN1KMT2A | |
| SCHEMBL24340866 | 0.77 | CKS1B (0.43) | MGLLMAPT | |
| SCHEMBL7669610 | 0.75 | ALDH1A1 (0.61) | LMNAHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL17532690 | 0.74 | EGFR (0.44) | LMNAHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL25835831 | 0.74 | LOXL2 (0.56) | LPAR1LPAR5MEN1KMT2AALDH1A1 | |
| SCHEMBL24340765 | 0.74 | MGLL (0.39) | LPAR1LPAR5MGLLALDH1A1MAPT | |
| SCHEMBL17532691 | 0.73 | HDAC1 (0.44) | LMNAHPGDALDH1A1MAPT | |
| SCHEMBL24340785 | 0.72 | MAPT (0.41) | LPAR1LPAR5MGLLMEN1KMT2A | |
| SCHEMBL26033083 | 0.72 | LOXL2 (0.46) | LPAR1LPAR5MGLLMEN1KMT2A | |
| SCHEMBL14640651 | 0.71 | NAMPT (0.49) | LMNAHPGDMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | LMNA 1652/4885MTNR1A 1317/4885MTNR1B 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.